BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
The primary findings of Phase 3 CALIBRATE were recently revealed during a presentation at the 2026 ECE. The results showcased the fast and long-lasting advantages of encaleret in ADH1, including significant improvements across crucial clinical measures.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments